Healthcare entity

Stevanato Group

Company STVN

All 1 tracked stories fall under one category: market-trends. Aware is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Source depth averages 14 original sources per story, versus 2.8 across the same-window beat baseline. Their average consequence score of 6 runs above the beat's 5.8 for that window.

Last mentioned: May 9, 2026

Entity pulse

Recent coverage · Stevanato Group

1 story
6 avg impact
100% positive
0% negative

Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.

  • 100% positive

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Stevanato Group

All 1 tracked stories fall under one category: market-trends. Aware is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Source depth averages 14 original sources per story, versus 2.8 across the same-window beat baseline. Their average consequence score of 6 runs above the beat's 5.8 for that window. We currently track 1 Healthcare story that mention Stevanato Group, all published on March 5, 2026.

Stories tracked
1
Sources per story
14

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 25 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Stevanato Group. Shared-story counts are live from our verified record — not editorial picks.

Key Data

ticker
STVN
name
Stevanato Group
price
45.2
change
2.15
changePct
5

Stories mentioning Stevanato Group 1

Market Trends Positive

GLP-1 Surge Drives Stevanato Growth as MedTech Sector Pivots to Efficiency

Stevanato Group reported robust 2025 results fueled by a 50% surge in GLP-1 related revenue, while medical device maker Pulmonx initiated aggressive cost-cutting measures following a U.S. revenue decline. The divergence highlights a shifting healthcare landscape where specialized biopharma supply chains are outperforming traditional niche medical devices.

14 sources

Stevanato Group is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.